BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 16813705)

  • 21. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
    Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Shinohara K; Fearn PA; Kattan MW; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):341-6. PubMed ID: 18597953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer.
    Lee WR; McQuellon RP; Case LD; deGuzman AF; McCullough DL
    J Urol; 1999 Aug; 162(2):403-6. PubMed ID: 10411047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
    Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer.
    Hollenbeck BK; Wei JT; Sanda MG; Dunn RL; Sandler HM
    Urology; 2004 May; 63(5):946-50. PubMed ID: 15134986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer.
    Sasaki T; Nakamura K; Shioyama Y; Ohga S; Toba T; Urashima Y; Yoshitake T; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Hiratsuka Y; Hirano T; Hanada K; Abe M; Fujisawa Y; Honda H
    Anticancer Res; 2006; 26(3B):2367-74. PubMed ID: 16821618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
    Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma.
    Windsor PM; Nicol KF; Potter J
    Cancer; 2004 Aug; 101(3):550-7. PubMed ID: 15274068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
    Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison.
    Pinkawa M; Piroth MD; Holy R; Fischedick K; Klotz J; Székely-Orbán D; Eble MJ
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):23-8. PubMed ID: 20832182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of local failure following prostate brachytherapy.
    Stone NN; Stock RG; White I; Unger P
    J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
    D'Amico AV; Renshaw AA; Loffredo B; Chen MH
    Cancer; 2007 Oct; 110(8):1723-8. PubMed ID: 17828774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
    J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up after triple treatment of prostate cancer stage pT3.
    Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
    Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in Japan.
    Sasaki T; Nakamura K; Ogawa K; Onishi H; Okamoto A; Koizumi M; Shioyama Y; Mitsumori M; Teshima T;
    BJU Int; 2009 Nov; 104(10):1462-6. PubMed ID: 19522869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatigue during head-and-neck radiotherapy: prospective study on 117 consecutive patients.
    Jereczek-Fossa BA; Santoro L; Alterio D; Franchi B; Fiore MR; Fossati P; Kowalczyk A; Canino P; Ansarin M; Orecchia R
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):403-15. PubMed ID: 17398020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
    Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):407-12. PubMed ID: 19211197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer - a prospective analysis.
    Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Holy R; Krenkel B; Eble MJ
    Radiother Oncol; 2008 Jul; 88(1):135-9. PubMed ID: 18022263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.